argenex (ARGX) Competitors

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gilead Sciences has higher revenue and earnings than argenex. Gilead Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

In the previous week, Gilead Sciences had 17 more articles in the media than argenex. MarketBeat recorded 24 mentions for Gilead Sciences and 7 mentions for argenex. Gilead Sciences' average media sentiment score of 0.80 beat argenex's score of 0.31 indicating that Gilead Sciences is being referred to more favorably in the media.

Gilead Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Gilead Sciences' net margin of -10.64%. argenex's return on equity of 43.59% beat Gilead Sciences' return on equity.

Gilead Sciences currently has a consensus target price of $158.78, suggesting a potential upside of 7.01%. argenex has a consensus target price of $1,158.61, suggesting a potential upside of 20.76%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Gilead Sciences.

Vertex Pharmaceuticals has a net margin of 35.00% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Vertex Pharmaceuticals' return on equity.

Vertex Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Vertex Pharmaceuticals presently has a consensus target price of $573.83, indicating a potential upside of 10.08%. argenex has a consensus target price of $1,158.61, indicating a potential upside of 20.76%. Given argenex's higher possible upside, analysts clearly believe argenex is more favorable than Vertex Pharmaceuticals.

Vertex Pharmaceuticals has higher revenue and earnings than argenex. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

In the previous week, Vertex Pharmaceuticals had 14 more articles in the media than argenex. MarketBeat recorded 21 mentions for Vertex Pharmaceuticals and 7 mentions for argenex. Vertex Pharmaceuticals' average media sentiment score of 0.74 beat argenex's score of 0.31 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Regeneron Pharmaceuticals had 8 more articles in the media than argenex. MarketBeat recorded 15 mentions for Regeneron Pharmaceuticals and 7 mentions for argenex. Regeneron Pharmaceuticals' average media sentiment score of 0.80 beat argenex's score of 0.31 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals has higher revenue and earnings than argenex. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Regeneron Pharmaceuticals' net margin of 27.86%. argenex's return on equity of 43.59% beat Regeneron Pharmaceuticals' return on equity.

Regeneron Pharmaceuticals currently has a consensus price target of $802.18, suggesting a potential upside of 1.63%. argenex has a consensus price target of $1,158.61, suggesting a potential upside of 20.76%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Regeneron Pharmaceuticals.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

60.3% of argenex shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to Moderna's net margin of -141.43%. argenex's return on equity of 43.59% beat Moderna's return on equity.

argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

argenex currently has a consensus price target of $1,158.61, suggesting a potential upside of 20.76%. Moderna has a consensus price target of $76.72, suggesting a potential downside of 60.43%. Given argenex's stronger consensus rating and higher possible upside, equities research analysts plainly believe argenex is more favorable than Moderna.

argenex has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

In the previous week, Moderna had 39 more articles in the media than argenex. MarketBeat recorded 46 mentions for Moderna and 7 mentions for argenex. argenex's average media sentiment score of 0.31 beat Moderna's score of 0.25 indicating that argenex is being referred to more favorably in the media.